Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;68(6):763-767.
doi: 10.1097/MPG.0000000000002333.

Clinically Evident Portal Hypertension: An Operational Research Definition for Future Investigations in the Pediatric Population

Affiliations

Clinically Evident Portal Hypertension: An Operational Research Definition for Future Investigations in the Pediatric Population

Lee M Bass et al. J Pediatr Gastroenterol Nutr. 2019 Jun.

Abstract

Portal hypertension (PHT) is a major cause of morbidity and mortality in pediatric liver diseases. Thus, research into causes and disease modifiers in PHT in these conditions is vitally important. PHT is rarely directly or indirectly measured in the assessment of children with chronic liver disease. A straightforward, reproducible definition of PHT could be invaluable for consistently identifying patients with PHT and for grouping these patients according to their risk of complications from their disease. We propose the term Clinically Evident Portal Hypertension (CEPH) to denote clinical findings that demonstrate evidence of elevated portal pressure. When CEPH criteria are met, PHT is highly likely to be present, although it is likely that PHT exists for variable periods of time before meeting CEPH criteria. Use of this research definition of CEPH will allow for consistent identification of these patients by clinicians in nearly any clinical setting and serve as a clinical milepost that may dictate future prognosis in pediatric patients with cirrhosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

LMB is on the speaker’s bureau for Mead Johnson Nutrition. BLS, LH, NPG, and JCM have no conflicts of interest.

References

    1. de Franchis R Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63(3):743–52. - PubMed
    1. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353(21):2254–61. - PubMed
    1. de Franchis R Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000;33(5):846–52. - PubMed
    1. Nagula S, Jain D, Groszmann RJ, et al. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 2006;44(1):111–7. - PubMed
    1. Shneider BL, Abel B, Haber B, et al. Portal hypertension in children and young adults with biliary atresia. J Pediatr Gastroenterol Nutr 2012;55(5):567–73. - PMC - PubMed

Publication types